Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBT Margin (2020 - 2025)

Historic EBT Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 47.17%.

  • Apellis Pharmaceuticals' EBT Margin rose 760600.0% to 47.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.59%, marking a year-over-year increase of 392400.0%. This contributed to the annual value of 25.18% for FY2024, which is 1075800.0% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its EBT Margin stood at 47.17% for Q3 2025, which was up 760600.0% from 23.35% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' EBT Margin peaked at 47.17% during Q3 2025, and registered a low of 35183.15% during Q2 2021.
  • For the 5-year period, Apellis Pharmaceuticals' EBT Margin averaged around 2402.7%, with its median value being 127.56% (2023).
  • Data for Apellis Pharmaceuticals' EBT Margin shows a peak YoY increase of 342305000bps (in 2022) and a maximum YoY decrease of -4941400bps (in 2022) over the last 5 years.
  • Over the past 5 years, Apellis Pharmaceuticals' EBT Margin (Quarter) stood at 244.79% in 2021, then crashed by -202bps to 738.92% in 2022, then soared by 92bps to 59.54% in 2023, then surged by 71bps to 16.97% in 2024, then skyrocketed by 378bps to 47.17% in 2025.
  • Its EBT Margin stands at 47.17% for Q3 2025, versus 23.35% for Q2 2025 and 55.09% for Q1 2025.